Vaccines
2 December 2015
NanoBio’s Chlamydia Vaccine Improves Clearance of Bacteria and Prevents Pelvic Inflammatory Disease in Mice1 December 2015
VALNEVA Reports Positive Phase II Results for its Clostridium Difficile Vaccine Candidate25 November 2015
Seqirus receives FDA approval for FLUAD™ (Influenza Vaccine, Adjuvanted) for adults aged 65 years and older22 November 2015
Long-term Survival Benefit Demonstrated in Phase 2 ReACT Study of RINTEGA(R) in Recurrent Bevacizumab-naive Glioblastoma19 November 2015
Vaxart Presents Positive Preclinical Data for Oral RSV Vaccine at RSV Vaccines for the World Conference13 November 2015
DBV Technologies Announces Enrollment of First Patient in Phase IIA Study in Pediatric Eosinophilic Esophagitis12 November 2015
Aimmune Therapeutics Reports Positive Findings for ARC002 Follow-On Phase 2 Study of AR101 for Treatment of Peanut Allergy12 November 2015
Immune Design Announces Start of Randomized Phase 2 Cancer Immunotherapy Combination Trial in Patients With Soft Tissue Sarcoma7 November 2015
Heat Biologics Reports HS-410 Phase 1 Bladder Cancer Trial Results at the Society for Immunotherapy of Cancer (SITC) Annual Meeting4 November 2015
Transgene Announces Dosing of First Patient with TG1050 for Treatment of Chronic Hepatitis B Infection3 November 2015
CyTuVax starts Phase I Clinical trial with the HBAI20 Hepatitis B vaccine for Non-responders3 November 2015
Bavarian Nordic Announces Results of a Phase 1 Trial Investigating Brachyury Specific Cancer Vaccine in Patients with Advanced Cancers3 November 2015
OSE Pharma receives positive opinion from several European countries to start pivotal Phase 3 trial of Tedopi®29 October 2015
MEDI7510 for Respiratory Syncytial Virus Advances to Phase 2 Leverages Immune Design’s GLAAS(TM) Discovery Platform29 October 2015
Immunovaccine’s Vaccine Candidate for Respiratory Syncytial Virus Is Well Tolerated in Volunteers in Phase 1 Clinical Trial27 October 2015
GSK’s candidate shingles vaccine demonstrates 90% efficacy against shingles in people 70 years of age and over23 October 2015
Novavax Initiates Phase 2 Safety and Immunogenicity Trial to Evaluate Annual Re-Dosing of the RSV F Vaccine in Older Adults19 October 2015
Genocea Announces Top-Line Results from Phase 2a Trial for Universal Pneumococcal Vaccine Candidate GEN-00419 October 2015
Inovio and Partner Advance MERS VaccineNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports